{
    "paper_id": "31d913e8f746c79b7627294e005dbc6064412b83",
    "metadata": {
        "title": "ARTICLE IN PRESS G Model ScienceDirect",
        "authors": [
            {
                "first": "B",
                "middle": [],
                "last": "El Boussadani",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "C",
                "middle": [],
                "last": "Benajiba",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "A",
                "middle": [],
                "last": "Aajal",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "A",
                "middle": [
                    "Ait"
                ],
                "last": "Brik",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "O",
                "middle": [],
                "last": "Ammour",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "J",
                "middle": [
                    "El"
                ],
                "last": "Hangouch",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "O",
                "middle": [],
                "last": "Oussama",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "B",
                "middle": [],
                "last": "Oussama",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "N",
                "middle": [],
                "last": "Tahiri",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            },
            {
                "first": "Z",
                "middle": [],
                "last": "Raissuni",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "universit\u00e9 Abdelmalek Essadi",
                    "location": {
                        "settlement": "Tanger",
                        "country": "Maroc"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "L'infection \u00e0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appel\u00e9e Coronavirus Disease 2019 (COVID-19) a pris naissance en Chine en d\u00e9cembre 2019. Elle est \u00e0 l'origine de pneumonies potentiellement mortelles. L'infection est d\u00e9clar\u00e9e pand\u00e9mie par l'OMS le 11 mars 2020. Le 01 avril 2020 l'OMS d\u00e9nombre 911 541 cas confirm\u00e9s de COVID-19, et 45 532 d\u00e9c\u00e8s.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Le COVID-19 peut avoir un impact direct sur le syst\u00e8me cardiovasculaire. Les maladies cardiovasculaires pr\u00e9existantes peuvent pr\u00e9disposer \u00e0 une infection par COVID-19 ou l'aggraver. Ainsi l'impact de l'infection semble \u00eatre plus intense si l'h\u00f4te pr\u00e9sente des comorbidit\u00e9s cardiovasculaires, d'autant plus qu'il s'agit le plus souvent de sujets \u00e2g\u00e9s fragiles et \u00e0 immunit\u00e9 r\u00e9duite. Les th\u00e9rapies pour COVID-19 peuvent entra\u00eener des effets ind\u00e9sirables cardiovasculaires \u00e0 la phase aigu\u00eb potentiellement graves et n\u00e9cessitant une surveillance rapproch\u00e9e. Les personnes atteintes de maladies cardiovasculaires infect\u00e9es par le virus ont un risque plus \u00e9lev\u00e9 d'effets ind\u00e9sirables, et sont consid\u00e9r\u00e9es de mauvais pronostic. Des effets cardiovasculaires chroniques passant par une perturbation du m\u00e9tabolisme lipidique sont \u00e9galement des cons\u00e9quences connues des coronavirus. L'objectif de cette revue est de caract\u00e9riser l'impact cardiovasculaire du COVID-19 et ses cons\u00e9quences potentielles chez les patients atteints de maladie cardiovasculaire \u00e9tablie. Nous allons \u00e9galement aborder les modalit\u00e9s de surveillance des traitements propos\u00e9s dans le COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Les infections virales respiratoires repr\u00e9sentent une part tr\u00e8s importante de la morbidit\u00e9 observ\u00e9e en pratique communautaire et hospitali\u00e8re et demeurent la principale cause de mortalit\u00e9 d'origine infectieuse. Elle reste une source majeure de pand\u00e9mies mondiales en raison de la transmission interhumaine rapide par voie respiratoire [1] .",
            "cite_spans": [
                {
                    "start": 335,
                    "end": 338,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "Depuis 1510, 14 pand\u00e9mies se sont succ\u00e9d\u00e9es, dont la grippe espagnole en 1918 consid\u00e9r\u00e9e comme la plus grave [2] . L'\u00e9pid\u00e9mie de SRAS (syndrome respiratoire aigu s\u00e9v\u00e8re li\u00e9 au coronavirus) en 2002 a \u00e9t\u00e9 responsable de 916 d\u00e9c\u00e8s parmi plus de 8000 patients dans 29 pays, suivis par l'\u00e9mergence du MERS-COV (Coronavirus du syndrome respiratoire du Moyen-Orient) en 2012, avec 800 d\u00e9c\u00e8s parmi 2254 patients dans 27 pays [3] .",
            "cite_spans": [
                {
                    "start": 109,
                    "end": 112,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 417,
                    "end": 420,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "La grippe aviaire et porcine demeure une pr\u00e9occupation pour l'OMS, m\u00eame si la mortalit\u00e9 reste similaire aux virus saisonniers pendant pand\u00e9mie de H1N1 en 2009 [1] .",
            "cite_spans": [
                {
                    "start": 159,
                    "end": 162,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "Fin 2019, une cohorte de patients pr\u00e9sentant une pneumopathie d'\u00e9tiologie inconnue d\u00e9clar\u00e9e \u00e0 Wuhan en Chine, annonce le d\u00e9but de la pand\u00e9mie COVID-19. Le 01 avril 2020, un total de 911 541 confirm\u00e9s cas (dont 45 532 d\u00e9c\u00e8s dans 152 pays) ont \u00e9t\u00e9 r\u00e9pertori\u00e9s par l'Organisation mondiale de la sant\u00e9. Bien que COVID-19 semble avoir une plus grande contagiosit\u00e9, sa mortalit\u00e9 est plus faible que le SRAS et MERS-COV. Cette infection COVID-19 est secondaire \u00e0 un virus d'origine zoonotique appel\u00e9 par l'OMS coronavirus 2 du syndrome respiratoire aigu (SARS-CoV-2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "Les manifestations cliniques sont domin\u00e9es par des sympt\u00f4mes respiratoires pouvant aller de la simple toux ou g\u00e8ne laryng\u00e9e jusqu'au SDRA (syndrome de d\u00e9tresse respiratoire aigu).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "L'atteinte cardiaque dans le COVID est pr\u00e9sente et grave, en effet le virus a un double effet au niveau cardiovasculaire : l'infection sera plus intense si l'h\u00f4te poss\u00e8de des comorbidit\u00e9s cardiovasculaires et, le virus peut lui-m\u00eame causer des l\u00e9sions cardiovasculaires potentiellement mortelles.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "En Italie on compte (52 %) de patient avec des ant\u00e9c\u00e9dents de maladie cardiovasculaire, 30 % souffrant de coronaropathie et 22 % avec un trouble du rythme de type fibrillation atriale [4] . Le Tableau 1 r\u00e9sume les principaux facteurs de risque et situations  cardiaques associ\u00e9es au COVID-19. L'atteinte cardiaque directe rapport\u00e9e chez les patients hospitalis\u00e9s est estim\u00e9e entre 7 et 17 % en fonction des s\u00e9ries, et constitue 59 % des d\u00e9c\u00e8s relatifs au SARS-COV 2 [5] . N\u00e9anmoins il s'agit des complications observ\u00e9es uniquement chez les patients hospitalis\u00e9s et non pas sur l'ensemble des sujets infect\u00e9s (Tableau 2).",
            "cite_spans": [
                {
                    "start": 184,
                    "end": 187,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 466,
                    "end": 469,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [
                {
                    "start": 193,
                    "end": 292,
                    "text": "Tableau 1 r\u00e9sume les principaux facteurs de risque et situations  cardiaques associ\u00e9es au COVID-19.",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19"
        },
        {
            "text": "L'atteinte cardiovasculaire au cours du COVID-19 est prouv\u00e9e dans de nombreux papiers r\u00e9cemment publi\u00e9s, elle est occasionn\u00e9e par diff\u00e9rents m\u00e9canismes directs et indirects. L\u00e9sion myocardique aigu\u00eb [12, 13] Myocardite [20] Syndrome coronarien aigu [18] Arythmie cardiaque et arr\u00eat cardiaque [21] Cardiomyopathie et insuffisance cardiaque [10] 3.1. Atteinte myocardique directe",
            "cite_spans": [
                {
                    "start": 199,
                    "end": 203,
                    "text": "[12,",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 204,
                    "end": 207,
                    "text": "13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 219,
                    "end": 223,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 249,
                    "end": 253,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 292,
                    "end": 296,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 339,
                    "end": 343,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [],
            "section": "Manifestations cardiovasculaires du COVID-19"
        },
        {
            "text": "Atteinte myocardique directe via le r\u00e9cepteur de l'enzyme de conversion de l'angiotensine 2 (ACE2), que les cardiomyocytes expriment de mani\u00e8re importante. Cela pourrait \u00eatre \u00e0 l'origine de v\u00e9ritables myocardites ; Selon l'\u00e9tude d'Oudit, l'ARN viral du SRAS-CoV a \u00e9t\u00e9 d\u00e9tect\u00e9 dans 35 % des coeurs humains autopsi\u00e9s pendant l'\u00e9pid\u00e9mie de SRAS \u00e0 Toronto [10] . Les m\u00eames auteurs ont confirm\u00e9 que le SARS-CoV peut causer une l\u00e9sion myocardique d\u00e9pendante de l'ACE2 (ACE2-dependent myocardial infection) [12] , identifi\u00e9 comme un r\u00e9cepteur fonctionnel pour les coronavirus (la mod\u00e9lisation mol\u00e9culaire une grande similitude structurelle entre les domaines r\u00e9cepteurs du SRAS-CoV et SARS-COV 2) [13] .",
            "cite_spans": [
                {
                    "start": 352,
                    "end": 356,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 500,
                    "end": 504,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 690,
                    "end": 694,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "ref_spans": [],
            "section": "Manifestations cardiovasculaires du COVID-19"
        },
        {
            "text": "Atteinte myocardique indirecte par infarctus de type 1 (rupture de plaque favoris\u00e9e par l'infection comme avec la grippe) ou de type 2 (secondaire \u00e0 une inad\u00e9quation de la demande et des apports myocardiques en oxyg\u00e8ne secondaire \u00e0 l'insuffisance respiratoire, orage cytokinique).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Atteinte myocardique indirecte par infarctus"
        },
        {
            "text": "L\u00e9sion myocardique aigu\u00eb (myocardial injury) : un certain nombre de malades admis pour une pneumopathie hypox\u00e9miante et/ou un syndrome de d\u00e9tresse respiratoire aigu\u00eb dans le cadre du COVID-19 d\u00e9velopperont des l\u00e9sions myocardiques aigu\u00ebs d\u00e9finies par une augmentation et ou baisse de la troponine associ\u00e9e \u00e0 une atteinte myocardique [14, 15] . Des diff\u00e9rences significatives en ce qui concerne les taux de la troponine ont \u00e9t\u00e9 not\u00e9es entre les patients gu\u00e9ris et ceux d\u00e9c\u00e9d\u00e9s [16] . Dans une m\u00e9ta-analyse ayant regroup\u00e9 341 patients, l'\u00e9l\u00e9vation de la troponine \u00e9tait plus importante dans les formes graves du COVID-19 et s'associe \u00e0 un pronostic p\u00e9joratif [17, 18] . Cependant, la troponine peut \u00eatre \u00e9lev\u00e9e chez les patients avec insuffisance r\u00e9nale chronique ou ceux qui d\u00e9veloppent une insuffisance r\u00e9nale aigu\u00eb dans le cadre du sepsis. Compte tenu de la fr\u00e9quence et de la nature non sp\u00e9cifique de l'\u00e9l\u00e9vation de la troponine chez les patients infect\u00e9s par COVID-19, il est conseill\u00e9 aux cliniciens de mesurer la troponine uniquement si le diagnostic d'infarctus aigu ou de myocardite est suspect\u00e9. L'\u00e9l\u00e9vation de la troponine et du BNP doit \u00eatre interpr\u00e9t\u00e9e dans le contexte global de l'infection (en confrontation avec les donn\u00e9es cliniques et d'autres techniques d'imagerie).",
            "cite_spans": [
                {
                    "start": 333,
                    "end": 337,
                    "text": "[14,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 338,
                    "end": 341,
                    "text": "15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 476,
                    "end": 480,
                    "text": "[16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 657,
                    "end": 661,
                    "text": "[17,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 662,
                    "end": 665,
                    "text": "18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "L\u00e9sion myocardique aigu\u00eb"
        },
        {
            "text": "Sur une s\u00e9rie de 150 cas de COVID-19, 68 d\u00e9c\u00e8s ont \u00e9t\u00e9 r\u00e9pertori\u00e9s avec 27 cas de myocardite dont 5 dites fulminantes [10] . D'autres auteurs ont d\u00e9crit des d\u00e9c\u00e8s sur des formes fulminantes avec des r\u00e9sultats d'autopsie montrant un infiltrat mononucl\u00e9aire dans le tissu myocardique [19, 20] . Une observation publi\u00e9e dans l'EHJ a montr\u00e9 l'efficacit\u00e9 de l'association cortico\u00efdes immunoglobulines dans le traitement d'un cas de myocardite fulminante \u00e0 coronavirus [21] .",
            "cite_spans": [
                {
                    "start": 118,
                    "end": 122,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 282,
                    "end": 286,
                    "text": "[19,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 287,
                    "end": 290,
                    "text": "20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 463,
                    "end": 467,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                }
            ],
            "ref_spans": [],
            "section": "Myocardite"
        },
        {
            "text": "Dans une cohorte de 137 patients admis pour COVID-19, 7,3 % ont pr\u00e9sent\u00e9 des palpitations [22] . La moiti\u00e9 des patients hospitalis\u00e9s en USI ont pr\u00e9sent\u00e9 une arythmie cardiaque, sans pr\u00e9ciser le type de ces troubles [8] . Cette pr\u00e9valence \u00e9lev\u00e9e peut \u00eatre expliqu\u00e9e par les troubles m\u00e9taboliques, hypoxie, stress neurohormonal et inflammatoire dans le contexte du SDRA. Cependant, il faut toujours penser \u00e0 une myocardite devant une arythmie maligne avec l\u00e9sion myocardique aigu\u00eb [16, 23] . Les extrasystoles ventriculaires (ESV) et l'amplitude des QRS sont \u00e0 surveiller. Ces myocardites fulminantes entra\u00eenent une diminution tr\u00e8s rapide de l'amplitude du QRS.",
            "cite_spans": [
                {
                    "start": 90,
                    "end": 94,
                    "text": "[22]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 215,
                    "end": 218,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 479,
                    "end": 483,
                    "text": "[16,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 484,
                    "end": 487,
                    "text": "23]",
                    "ref_id": "BIBREF22"
                }
            ],
            "ref_spans": [],
            "section": "Arythmie cardiaque"
        },
        {
            "text": "Dans la s\u00e9rie de Zhou et al. [7] , une insuffisance cardiaque a \u00e9t\u00e9 observ\u00e9e chez 23 % des patients pr\u00e9sentant une COVID-19 en rapport surtout avec une d\u00e9compensation d'une dysfonction ventriculaire gauche pr\u00e9existante, avec une mortalit\u00e9 importante. La pouss\u00e9e d'insuffisance cardiaque sur cardiopathie pose \u00e9galement un probl\u00e8me de diagnostic initial et peu retarder le diagnostic du COVID-19 et augmenter la contagiosit\u00e9, \u00e9l\u00e9ment important \u00e0 prendre en consid\u00e9ration en cas de suspicion de l'infection \u00e0 coronavirus chez un patient cardiaque.",
            "cite_spans": [
                {
                    "start": 29,
                    "end": 32,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Cardiomyopathie et insuffisance cardiaque"
        },
        {
            "text": "Un tableau d'insuffisance cardiaque droite avec hypertension pulmonaire a \u00e9t\u00e9 observ\u00e9 surtout dans un contexte de SDRA. Certains patients ont pr\u00e9sent\u00e9 des tableaux de choc cardiog\u00e9nique ou mixte, d'o\u00f9 l'int\u00e9r\u00eat de la r\u00e9alisation d'une TDM thoracique une \u00e9chographie cardiaque et le dosage du peptide natriur\u00e9tique pour clarifier le diagnostic [24, 25] . Dans certaines situations une assistance circulatoire s'impose (ECMO veino-veineuse vs veinoart\u00e9rielle), avec des r\u00e9sultats malheureusement d\u00e9cevants [26] .",
            "cite_spans": [
                {
                    "start": 343,
                    "end": 347,
                    "text": "[24,",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 348,
                    "end": 351,
                    "text": "25]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 504,
                    "end": 508,
                    "text": "[26]",
                    "ref_id": "BIBREF25"
                }
            ],
            "ref_spans": [],
            "section": "Cardiomyopathie et insuffisance cardiaque"
        },
        {
            "text": "Le COVID-19 est associ\u00e9 \u00e0 un risque thromboembolique \u00e9lev\u00e9, plusieurs facteurs sont incrimin\u00e9s : une immobilisation prolong\u00e9e, L'inflammation responsable d'un \u00e9tat d'hypercoagulabilit\u00e9 et de dysfonction endoth\u00e9liale. Entre autres des taux \u00e9lev\u00e9s de Ddim\u00e8res D (> 1 g/L) \u00e9taient fortement corr\u00e9l\u00e9s \u00e0 une mortalit\u00e9 intra-hospitali\u00e8re \u00e9lev\u00e9e [7] . La thrombo-prophylaxie optimale pour les patients COVID-19, n'est pas encore bien \u00e9tudi\u00e9e, c'est pourquoi il faut appliquer les protocoles d\u00e9j\u00e0 approuv\u00e9s de prophylaxie [27] .",
            "cite_spans": [
                {
                    "start": 339,
                    "end": 342,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 514,
                    "end": 518,
                    "text": "[27]",
                    "ref_id": "BIBREF26"
                }
            ],
            "ref_spans": [],
            "section": "Maladie thromboembolique veineuse"
        },
        {
            "text": "3.8. Cas particulier de la prise en charge des syndromes coronariens aigus SCA Des auteurs italiens ont d\u00e9crit des cas de MINOCA test\u00e9s positifs pour COVID-19 [28] . Mais jusqu'\u00e0 ce jour aucun cas de SCA dans le cadre de COVID-19 n'a \u00e9t\u00e9 d\u00e9crit. N\u00e9anmoins, les formes graves du COVID-19 peuvent pr\u00e9senter un risque de rupture de la plaque d'ath\u00e9rome chez certain patients [7] d'o\u00f9 le d\u00e9veloppement d'un protocole de soins pour Les patients admis pour SCA dans le cadre d'un COVID-19 [29] . Ci-dessous les Fig. 1 et 2 r\u00e9sumant la conduite \u00e0 tenir devant les syndromes coronariens aigus avec et sans susd\u00e9calage du segment ST, STEMI et NSTEMI. En m\u00eame temps, une diminution des patients hospitalis\u00e9s pour SCA a \u00e9t\u00e9 observ\u00e9e dans la plupart des pays dont la France. Cette baisse peut \u00eatre expliqu\u00e9e par la limitation des activit\u00e9s physiques \u00e0 cause du confinement de la population avec moins de situations de stress susceptibles de d\u00e9clencher la rupture de plaques d'ath\u00e9rome, et par la crainte d'une probable contagion \u00e0 l'h\u00f4pital qui pousse les patients \u00e0 consulter peu m\u00eame en cas de sympt\u00f4mes.",
            "cite_spans": [
                {
                    "start": 159,
                    "end": 163,
                    "text": "[28]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 372,
                    "end": 375,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 483,
                    "end": 487,
                    "text": "[29]",
                    "ref_id": "BIBREF28"
                }
            ],
            "ref_spans": [
                {
                    "start": 505,
                    "end": 516,
                    "text": "Fig. 1 et 2",
                    "ref_id": "FIGREF0"
                }
            ],
            "section": "Maladie thromboembolique veineuse"
        },
        {
            "text": "Les mesures pr\u00e9ventives sont actuellement la meilleure strat\u00e9gie de lutte contre le COVID-19. Alors que des vaccins et des anticorps monoclonaux contre le SRAS-CoV-2 sont en cours de d\u00e9veloppement, un certain nombre d'autres th\u00e9rapies sont utilis\u00e9s, d'o\u00f9 l'importance de revoir les effets ind\u00e9sirables des mol\u00e9cules utilis\u00e9es et les \u00e9ventuelles interaction avec le syst\u00e8me cardiocirculatoire.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Interactions coeur/traitement du COVID-19"
        },
        {
            "text": "Le lopinavir/ritonavir peut entra\u00eener un allongement du QT, en particulier chez les patients suivis pour un syndrome de QT long cong\u00e9nital ou ceux qui prennent d'autres m\u00e9dicaments qui allongent l'intervalle QT [30] . Le QTc long si > 440 ms chez l'homme, > 460 ms chez la femme. La dur\u00e9e de l'intervalle QT doit se mesurer \u00e0 des fr\u00e9quences entre 60 et 85/mn dans les d\u00e9rivations o\u00f9 l'onde T est la plus ample et o\u00f9 le retour \u00e0 la ligne iso\u00e9lectrique est le plus net (souvent en V2), depuis le d\u00e9but du QRS jusqu'\u00e0 la jonction entre la tangente de la pente descendante maximale de l'onde T avec la ligne iso\u00e9lectrique Dans ces conditions, QT pathologique si > 440 ms (Fig. 3) . Si la FC est moins de 60 battements par minute (Bpm) et au-del\u00e0 de 85 bpm, on doit corriger le QT (Bazett), QTc = QTm/V RR.",
            "cite_spans": [
                {
                    "start": 211,
                    "end": 215,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [
                {
                    "start": 667,
                    "end": 675,
                    "text": "(Fig. 3)",
                    "ref_id": "FIGREF2"
                }
            ],
            "section": "Les antiviraux"
        },
        {
            "text": "Un ajustement du QTc s'impose chez les patients ayant des QRS larges, ayant une stimulation ventriculaire ou un bloc de branche gauche complet en appliquant une formule qui prend en consid\u00e9ration la largeur du QRS ; QTC (ajust\u00e9) = QTc \u2212 (QRS \u2212 100).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Les antiviraux"
        },
        {
            "text": "Quand le QTc > 500 ms le risque de mort subite devient significatif, il faut confier le malade \u00e0 une prise en charge sp\u00e9cialis\u00e9e en milieu hospitalier.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Les antiviraux"
        },
        {
            "text": "Le ribavirine et le lopinavir peuvent interagir avec les anticoagulants : la ribavirine a des effets variables sur la warfarine [31] et l'association lopinavir/ritonavir peut n\u00e9cessiter une r\u00e9duction de la dose voire l'arr\u00eat de certains AOD [32, 33] .",
            "cite_spans": [
                {
                    "start": 128,
                    "end": 132,
                    "text": "[31]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 241,
                    "end": 245,
                    "text": "[32,",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 246,
                    "end": 249,
                    "text": "33]",
                    "ref_id": "BIBREF32"
                }
            ],
            "ref_spans": [],
            "section": "Les antiviraux"
        },
        {
            "text": "Le lopinavir/ritonavir peut interf\u00e9rer avec les inhibiteurs de P2Y12 entra\u00eenant une diminution des concentrations s\u00e9riques du clopidogrel et du prasugrel et une augmentation des concentrations s\u00e9riques du ticagr\u00e9lor [34] . Vu le risque thrombotique/h\u00e9morragique, des approches guid\u00e9es par des tests d'activit\u00e9 plaquettaire peuvent \u00eatre envisageable [35] . Les statines peuvent \u00e9galement interagir avec le lopinavir/ritonavir avec un risque majeur de rhabdomyolyse. La lovastatine et la simvastatine, en particulier, sont contre-indiqu\u00e9es en cas de co-administration avec le lopinavir/ritonavir. D'autres statines comme l'atorvastatine et la rosuvastatine, peuvent \u00eatre administr\u00e9 \u00e0 des faibles doses [30] . Le Tableau 3 r\u00e9sume les interactions des antiviraux et les ajustements th\u00e9rapeutiques possibles [5] .",
            "cite_spans": [
                {
                    "start": 216,
                    "end": 220,
                    "text": "[34]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 349,
                    "end": 353,
                    "text": "[35]",
                    "ref_id": "BIBREF34"
                },
                {
                    "start": 700,
                    "end": 704,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 803,
                    "end": 806,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Les antiviraux"
        },
        {
            "text": "Il s'agit d'un antipalud\u00e9en de synth\u00e8se qui bloque l'activit\u00e9 virale en augmentant le pH endosomal, avec la d\u00e9monstration in vitro d'une inhibition du virus SRAS-CoV2 [36, 37] . La chloroquine est actuellement au coeur d'une vaste pol\u00e9mique, Raoult et al. ont expos\u00e9 les r\u00e9sultats de leur \u00e9tude non randomis\u00e9e qui a analys\u00e9 24 patients atteints du coronavirus, les 3/4 \u00e9taient gu\u00e9ris en 6 jours apr\u00e8s avoir re\u00e7 u de la chloroquine et surtout en association avec l'azithromycine [38] . Vu qu'il ne s'agissait pas d'une \u00e9tude randomis\u00e9e et vu le nombre limit\u00e9 de patients, cette \u00e9tude a \u00e9t\u00e9 largement critiqu\u00e9e en France. En revanche, il y a eu depuis 2 \u00e9tudes randomis\u00e9es chinoises \u00e0 \u00e9chantillons tr\u00e8s limit\u00e9s, l'une en double aveugle, portant sur (2 \u00d7 15) patients avec des r\u00e9sultats n\u00e9gatifs [39] , et l'autre encore ouverte, les r\u00e9sultats pr\u00e9liminaires concernant (2 \u00d7 31) patients se pr\u00e9sentent comme positive en cas d'introduction pr\u00e9coce du traitement [40] . Le minist\u00e8re de la sant\u00e9 au Maroc en concertation avec le comit\u00e9 scientifique et technique du programme national de lutte contre le coronavirus a d\u00e9cid\u00e9 le 23 mars 2020 d'adopter le protocole th\u00e9rapeutique a base d'hydroxychloroquine (200 mg \u00d7 3) et azythromycine (1 g le premier jour puis 500 mg/j pendant 3 jours) dans les diff\u00e9rents h\u00f4pitaux du royaume. Cette d\u00e9cision d'introduction pr\u00e9coce du traitement sous surveillance m\u00e9dicale semble \u00eatre justifi\u00e9e puisque dans les tableaux graves, notamment de SDRA, les pr\u00e9l\u00e8vements \u00e0 la recherche du virus sont souvent n\u00e9gatives [40] .",
            "cite_spans": [
                {
                    "start": 167,
                    "end": 171,
                    "text": "[36,",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 172,
                    "end": 175,
                    "text": "37]",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 478,
                    "end": 482,
                    "text": "[38]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 793,
                    "end": 797,
                    "text": "[39]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 957,
                    "end": 961,
                    "text": "[40]",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 1539,
                    "end": 1543,
                    "text": "[40]",
                    "ref_id": "BIBREF39"
                }
            ],
            "ref_spans": [],
            "section": "La chloroquine/hydroxychloroquine"
        },
        {
            "text": "La chloroquine a un mode d'action proche de la quinidine et des anti-arythmiques de la classe I de Vaughan-Williams. Ces propri\u00e9t\u00e9s \u00ab quinidine-like \u00bb expliquent l'effet stabilisant de membrane et le risque de la toxicit\u00e9 cardiaque surtout lors des administrations rapides par voie IV ou lors des intoxications aigu\u00ebs volontaires (les doses toxiques chez l'adulte sont de 2 g et les doses l\u00e9tales de 2,5 g). \u00c0 dose th\u00e9rapeutique au long cours, on peut observer parfois un aplatissement de l'onde T et/ou un allongement de l'intervalle QT en particulier lors de la prise concomitante d'un autre m\u00e9dicament allongeant le QT comme l'azithromycine. Ces anomalies n'ont pas de cons\u00e9quence clinique et r\u00e9gressent apr\u00e8s quelques jours [41] . Les troubles du rythmes et/ou conductifs graves sont surtout observ\u00e9s \u00e0 des doses toxiques (\u2265 2 g) n\u00e9cessitant une prise en charge sp\u00e9ciale [42] .",
            "cite_spans": [
                {
                    "start": 728,
                    "end": 732,
                    "text": "[41]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 875,
                    "end": 879,
                    "text": "[42]",
                    "ref_id": "BIBREF41"
                }
            ],
            "ref_spans": [],
            "section": "La chloroquine/hydroxychloroquine"
        },
        {
            "text": "De rares observations de cardiomyopathie restrictive/dilat\u00e9e ont \u00e9t\u00e9 rapport\u00e9 lors des traitements au long cours [43] .",
            "cite_spans": [
                {
                    "start": 113,
                    "end": 117,
                    "text": "[43]",
                    "ref_id": "BIBREF42"
                }
            ],
            "ref_spans": [],
            "section": "La chloroquine/hydroxychloroquine"
        },
        {
            "text": "En raison de l'inhibition du CYP2D6, la chloroquine peut augmenter la concentration de certains b\u00eata-bloquants d'o\u00f9 la n\u00e9cessit\u00e9 d'une surveillance de la FC et de la pression art\u00e9rielle et ajustement sp\u00e9cialis\u00e9es des doses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La chloroquine/hydroxychloroquine"
        },
        {
            "text": "Une surveillance plus proche est pr\u00e9conis\u00e9e en particulier en cas de co-prescription avec l'azithromycine, un ECG doit \u00eatre r\u00e9alis\u00e9 avant le d\u00e9but du traitement avec la mesure du QTc puis 3 \u00e0 4 h suivant la premi\u00e8re administration (au concentration max suppos\u00e9 de l'hydroxychloroquine \u00b1 azithromycine), puis 2 fois par semaine pendant la dur\u00e9e du traitement et en cas de sympt\u00f4me pouvant faire \u00e9voquer un trouble du rythme cardiaque (palpitations brusques et br\u00e8ves, syncope, crise comitiale. . .). Si le QTc est \u2265 500 ms, le traitement doit \u00eatre diminu\u00e9 ou arr\u00eat\u00e9 en fonction de la d\u00e9cision du clinicien, et un monitoring cardiaque continu mis en place jusqu'\u00e0 normalisation de l'ECG [44] . Le risque de trouble du rythme est major\u00e9 en cas d'hypokali\u00e9mie fr\u00e9quente dans les sepsis. Tout signe \u00e9voquant une instabilit\u00e9 rythmique doit inciter \u00e0 faire un ECG.",
            "cite_spans": [
                {
                    "start": 685,
                    "end": 689,
                    "text": "[44]",
                    "ref_id": "BIBREF43"
                }
            ],
            "ref_spans": [],
            "section": "La chloroquine/hydroxychloroquine"
        },
        {
            "text": "En effet le risque de torsades de pointes est r\u00e9el au-del\u00e0 d'une mesure du QTc, sup\u00e9rieure \u00e0 500 ms, une surveillance de la kali\u00e9mie et de la magn\u00e9s\u00e9mie dans ces rares cas s'impose, et l'\u00e9quipe soignante doit \u00eatre pr\u00eate \u00e0 monter une sonde provisoire de stimulation si n\u00e9cessaire. Il faut toujours corriger ces facteurs extrins\u00e8ques pour permettre une prescription dans les meilleures conditions. La Fig. 4 propose un sch\u00e9ma de surveillance cardiologique pour les patients sous traitement \u00e0 base d'hydroxychloroquine. (Sch\u00e9ma de surveillance all\u00e9g\u00e9 adapt\u00e9 au contexte de l'\u00e9pid\u00e9mie).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 399,
                    "end": 405,
                    "text": "Fig. 4",
                    "ref_id": null
                }
            ],
            "section": "La chloroquine/hydroxychloroquine"
        },
        {
            "text": "Propos\u00e9e pour les formes graves du COVID-19 dont on conna\u00eet ses effets sur le m\u00e9tabolisme hydrosod\u00e9 avec le risque d'HTA, peut \u00e9galement interagir avec la warfarine via un m\u00e9canisme non d\u00e9crit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La m\u00e9thylprednisolone"
        },
        {
            "text": "L'observance th\u00e9rapeutique peut \u00eatre difficile chez les patients cardiaques admis pour une infection \u00e0 COVID-19 grave avec un risque de d\u00e9compensation et de d\u00e9c\u00e8s. Il faut souligner la diminution de la r\u00e9action immunitaire chez les patients prenant des cortico\u00efdes sans une indication obligatoire, risquant d'aggraver le tableau clinique.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La m\u00e9thylprednisolone"
        },
        {
            "text": "L'enzyme de conversion de l'angiotensine 2, prot\u00e9ine membranaire int\u00e9grale de type I qui sert de nombreux fonctions physiologiques, semble jouer un r\u00f4le pour la p\u00e9n\u00e9tration du virus au niveau cellulaire comme cela a \u00e9t\u00e9 d\u00e9montr\u00e9 dans plusieurs \u00e9tudes sur le SRAS-CoV2 [10] .",
            "cite_spans": [
                {
                    "start": 268,
                    "end": 272,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [],
            "section": "Le d\u00e9bat pour l'arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone"
        },
        {
            "text": "Il est fortement exprim\u00e9 dans les cellules alv\u00e9olaires pulmonaires, fournissant le principal site d'entr\u00e9e virus chez des h\u00f4tes humains [21, 18] .",
            "cite_spans": [
                {
                    "start": 136,
                    "end": 140,
                    "text": "[21,",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 141,
                    "end": 144,
                    "text": "18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "Le d\u00e9bat pour l'arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone"
        },
        {
            "text": "Le coronavirus se lie aux cellules exprimant les r\u00e9cepteurs viraux appropri\u00e9s, en particulier les r\u00e9cepteurs ACE2 [45] augmentant ainsi la sensibilit\u00e9 au virus. En revanche, d'autres \u00e9tudes montrent que l'IEC/ARAII peut potentialiser la fonction de protection pulmonaire de l'ACE2, qui est un inhibiteur de l'angiotensine II. Ainsi, les implications th\u00e9rapeutiques pour la th\u00e9rapie IEC/ARAII pendant L'infection \u00e0 COVID-19 ne sont pas claires. Dans l'ensemble, les donn\u00e9es sont insuffisantes pour sugg\u00e9rer des connexions m\u00e9caniques entre la th\u00e9rapie IEC/ARAII et la contamination par le COVID-19. Ainsi en absence de donn\u00e9es cliniques, selon la derni\u00e8re publication dans le NEJM, the American College of Cardiology, and the American Society of Heart Failure [46] , on ne recommande pas l'arr\u00eat du traitement IEC, ARAII chez les patients atteints du nouveau coronavirus d\u00e9j\u00e0 sous traitement IEC/ARAII pour HTA, insuffisance cardiaque, ou cardiopathie isch\u00e9mique sauf dans certaines situations qui contre-indiquent leurs continuations (insuffisance r\u00e9nale, sepsis, \u00e9tat de choc) (Fig. 5 ).",
            "cite_spans": [
                {
                    "start": 114,
                    "end": 118,
                    "text": "[45]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 758,
                    "end": 762,
                    "text": "[46]",
                    "ref_id": "BIBREF45"
                }
            ],
            "ref_spans": [
                {
                    "start": 1077,
                    "end": 1084,
                    "text": "(Fig. 5",
                    "ref_id": "FIGREF3"
                }
            ],
            "section": "Le d\u00e9bat pour l'arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone"
        },
        {
            "text": "Les \u00e9pid\u00e9mies de maladies respiratoires virales menacent la sant\u00e9 publique et peuvent avoir des manifestations extrapulmonaires notamment cardiologiques avec des cons\u00e9quences \u00e0 la phase aigu\u00eb et \u00e0 long terme. Les maladies cardiovasculaires pr\u00e9existantes peuvent contribuer \u00e0 des r\u00e9sultats cliniques pr\u00e9coces d\u00e9favorables. La prise en charge interdisciplinaire des cas s\u00e9v\u00e8res et un suivi clinique prolong\u00e9 sont donc essentiels.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion"
        },
        {
            "text": "Les auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eats.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D\u00e9claration de liens d'int\u00e9r\u00eats"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "EMC -AKOS (Trait\u00e9 de M\u00e9decine",
            "authors": [
                {
                    "first": "Lina",
                    "middle": [
                        "B"
                    ],
                    "last": "Grippe",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "",
            "volume": "12",
            "issn": "",
            "pages": "1--11",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "The recent wave of 'Spanish' flu historiography",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Howard",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Soc Hist Med",
            "volume": "27",
            "issn": "4",
            "pages": "789--808",
            "other_ids": {
                "DOI": [
                    "10.1093/shm/hku066"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Les infections \u00e0 coronavirus humains",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Kin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Vabret",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Rev Francoph Lab",
            "volume": "2016",
            "issn": "487",
            "pages": "25--33",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1093/shm/hku066"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Characteristics of COVID-19 patients dying in Italy",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Cardiovascular considerations for patients, health care workers, and health systems during the Coronavirus disease 2019 (COVID-19) pandemic",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Driggin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "V"
                    ],
                    "last": "Madhavan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Bikdeli",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chuich",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Laracy",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Bondi-Zoccai",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Am Coll Cardiol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jacc.2020.03.031"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Clinical characteristics of Coronavirus Disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "Y"
                    ],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/j.jacc.2020.03.031"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan. China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Ruan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Intensive Care Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Intern Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "SARScoronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "Y"
                    ],
                    "last": "Oudit",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Kassiri",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "P"
                    ],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Poutanen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Penninger",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Eur J Clin Invest",
            "volume": "39",
            "issn": "",
            "pages": "618--643",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Niu",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and nonelevated troponins",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Sarkisian",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Saaby",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Poulsen",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Am J Med",
            "volume": "129",
            "issn": "",
            "pages": "5--446",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Fourth universal definition of myocardial infarction",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Thygesen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Alpert",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Jaffe",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Am Coll Cardiol",
            "volume": "72",
            "issn": "",
            "pages": "2231--64",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Lippi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Lavie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Prog Cardiovasc Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "L"
                    ],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "G"
                    ],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin",
            "authors": [
                {
                    "first": "Hongde",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Fenglian",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "Xin",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Yuan",
                    "middle": [],
                    "last": "Fang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Eur Heart J",
            "volume": "190",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/eurheartj/ehaa190"
                ]
            }
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Pathological findings of COVID-19 associated with acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/eurheartj/ehaa190"
                ]
            }
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Sci China Life Sci",
            "volume": "63",
            "issn": "",
            "pages": "364--74",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "Y"
                    ],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Chin Med J (Engl)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "SARS-CoV-2: a potential novel etiology of fulminant myocarditis",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "W"
                    ],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Herz",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Acute respiratory distress syndrome: the Berlin Definition",
            "authors": [
                {
                    "first": "Adt",
                    "middle": [],
                    "last": "Force",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "M"
                    ],
                    "last": "Ranieri",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "D"
                    ],
                    "last": "Rubenfeld",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "JAMA",
            "volume": "307",
            "issn": "",
            "pages": "2526--2559",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Karmpaliotis",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Kirtane",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "P"
                    ],
                    "last": "Ruisi",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Chest",
            "volume": "131",
            "issn": "",
            "pages": "964--71",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Maclaren",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Brodie",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Witt",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Nieuwlaat",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "P"
                    ],
                    "last": "Clark",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Blood Adv",
            "volume": "2",
            "issn": "",
            "pages": "3257--91",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "TCT the Heat Beat: COVID-19 and the Heart: Insights from the Front Lines",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Wood",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Pan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Intensive Care Med",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1007/s00134-020-05993-9"
                ]
            }
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert",
            "authors": [],
            "year": 2013,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1007/s00134-020-05~993-9"
                ]
            }
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "D"
                    ],
                    "last": "Decarolis",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Westanmo",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "C"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Boese",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Walquist",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "S"
                    ],
                    "last": "Rector",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Ann Pharmacother",
            "volume": "50",
            "issn": "",
            "pages": "909--926",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "E"
                    ],
                    "last": "Frost",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Byon",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Br J Clin Pharmacol",
            "volume": "79",
            "issn": "",
            "pages": "838--884",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Mueck",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Kubitza",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Becka",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Br J Clin Pharmacol",
            "volume": "76",
            "issn": "",
            "pages": "455--66",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Marsousi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Daali",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Fontana",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Clin Pharmacokinet",
            "volume": "57",
            "issn": "",
            "pages": "1347--54",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Angiolillo",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Rollini",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "F"
                    ],
                    "last": "Storey",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Circulation",
            "volume": "136",
            "issn": "",
            "pages": "1955--75",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "269--71",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Biosci Trends",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "20",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "XIA, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Chen Jun",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Liu Danping",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Liu Ping",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Xu Qingnian",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J Zhejiang Uni",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial",
            "authors": [
                {
                    "first": "Zhaowei",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Jijia",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Zongwei",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Shan",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Shoumeng",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.22.20040758"
                ]
            }
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Cardiotoxicity of antimalarial drugs",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "White",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Lancet Infect Dis",
            "volume": "7",
            "issn": "",
            "pages": "549--58",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.22.20040758"
                ]
            }
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Treatment of acute chloroquine poisoning: a 5-year experience",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Clemessy",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Taboulet",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Hoffman",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Crit Care Med",
            "volume": "24",
            "issn": "7",
            "pages": "1189--95",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "La toxicit\u00e9 cardiaque des antipalud\u00e9ens",
            "authors": [
                {
                    "first": "Le",
                    "middle": [],
                    "last": "Maitre",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Med Mal Infect",
            "volume": "29",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Chloroquine et hydroxychloroquine : Point d'information \u00e0 destination des professionnels de sant\u00e9 R\u00e9seau fran\u00e7 ais des Centres r\u00e9gionaux de Pharmacovigilance",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "22",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "Y"
                    ],
                    "last": "Ge",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "L"
                    ],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "503",
            "issn": "",
            "pages": "535--543",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "FHM Heart Groups: patients with COVID-19 should continue ACE inhibitors and ARBs",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "G"
                    ],
                    "last": "Fairchild",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "Di"
                    ],
                    "last": "Francesco",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Prise en charge du syndrome coronarien aigu sans sus-d\u00e9calage du segment ST NSTEMI dans le COVID-19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Prise en charge du syndrome coronarien aigu avec sus-d\u00e9calage du segment ST STEMI dans le COVID 19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Mesure QTc.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "sugg\u00e8rent que les inhibiteurs de l'ECA (IEC) et les bloqueurs des r\u00e9cepteurs de l'angiotensine (ARAII) peut r\u00e9guler positivement l'ACE2, Relation entre la pathog\u00e9nicit\u00e9 virale, les r\u00e9cepteurs ACE2 et la protection pulmonaire, ainsi que les effets potentiels sur l'inhibition de la r\u00e9nine-angiotensinealdost\u00e9rone.",
            "latex": null,
            "type": "figure"
        },
        "TABREF1": {
            "text": "Fr\u00e9quence relative des facteurs de risque cardiovasculaire ou des conditions cardiovasculaires sous-jacentes dans la cohorte COVID-19.",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Fig. 4. Surveillance cardiologique du traitement \u00e0 l'hydroxychloroquine COVID 19.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "Nos remercions le Pr Abdelhamid Mostaghfir pour la relecture de l'article.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Remerciements"
        }
    ]
}